Histopathologic tumor spreading in primary ovarian cancer with modified posterior exenteration

World Journal of Surgical Oncology

Makio Shozu²  Takako Kiyokawa³  Shinichi Tate²  Kyoko Nishikimi²  Kazuyoshi Kato¹ 

[1] Present address: Department of Gynecology, Cancer Institute Hospital, 3-8-31 Ariake, Koutou-ku 135-8550, Tokyo, Japan;Department of Gynecology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku 260-8670, Chiba, Japan;Department of Molecular Pathology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku 260-8670, Chiba, Japan

关键词: Interval debulking surgery;    Primary debulking surgery;    Histopathology;    Modified posterior exenteration;    Ovarian cancer;   

Others  :  1221424
DOI  :  10.1186/s12957-015-0647-x

 received in 2015-05-05, accepted in 2015-07-14,  发布年份 2015

【 摘 要 】

Background

To achieve optimal cytoreduction for advanced-stage ovarian cancer, modified posterior exenteration is the most frequently performed bowel surgery. We assessed the extents of tumor spreading in the rectosigmoid wall and pelvic side wall in modified posterior exenteration specimens during primary debulking surgery (PDS) and interval debulking surgery (IDS) following neoadjuvant chemotherapy, and compared the validity of selecting this surgical procedure in the patients undergoing PDS with that in the patients undergoing IDS.

Methods

Clinicopathological data from consecutive patients who had undergone a modified posterior exenteration for primary ovarian, tubal, and peritoneal cancer at our institution between April 2008 and March 2013 was retrospectively reviewed.

Results

A total of 75 patients (38 in PDS and 37 in IDS) were included in this study. Tumor involvement of the rectosigmoid was histopathologically confirmed in 65 % of the specimens. Though the extent of tumor spreading in the rectosigmoid was deeper in PDS than in IDS, the frequency of tumor involvement of the rectosigmoid in patients who had undergone modified posterior exenteration during PDS was equivalent to that in the IDS group. Lateral tumor spreading to the side wall(s) was histopathologically confirmed in 53 % of the patients in whom a pelvic side wall resection had been performed.

Conclusions

During both PDS and IDS for ovarian cancer presenting with tumor involvement of the cul-de-sac, close inspection and palpation by gynecologic oncologists may enable the extent of tumor spreading in the pelvis to be estimated, enabling valid decisions as to whether an en bloc resection of the pelvic tumors together with the rectosigmoid and the pelvic side wall might or might not be appropriate.

【 授权许可】

   
2015 Kato et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002; 20:1248-59.
• [2]Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA et al.. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009; 114:26-31.
• [3]Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009; 115:1234-44.
• [4]Thigpen T, duBois A, McAlpine J, DiSaia P, Fujiwara K, Hoskins W et al.. First-line therapy in ovarian cancer trials. Int J Gynecol Cancer. 2011; 21:756-62.
• [5]Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N et al.. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363:943-53.
• [6]Eisenkop SM, Nalick RH, Teng NN. Modified posterior exenteration for ovarian cancer. Obstet Gynecol. 1991; 78:879-85.
• [7]Aletti GD, Podratz KC, Jones MB, Cliby WA. Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. J Am Coll Surg. 2006; 203:521-6.
• [8]Obermair A, Hagenauer S, Tamandl D, Clayton RD, Nicklin JL, Perrin LC et al.. Safety and efficacy of low anterior en bloc resection as part of cytoreductive surgery for patients with ovarian cancer. Gynecol Oncol. 2001; 83:115-20.
• [9]Bristow RE, del Carmen MG, Kaufman HS, Montz FJ. Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. J Am Coll Surg. 2003; 197:565-74.
• [10]Richardson DL, Mariani A, Cliby WA. Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. Gynecol Oncol. 2006; 103:667-72.
• [11]Höckel M. Laterally extended endopelvic resection (LEER)—principles and practice. Gynecol Oncol. 2008; 111:S13-7.
• [12]Kato K, Tate S, Nishikimi K, Shozu M. Bladder function after modified posterior exenteration for primary gynecological cancer. Gynecol Oncol. 2013; 129:229-33.
• [13]Hertel H, Diebolder H, Herrmann J, Köhler C, Kühne-Heid R, Possover M et al.. Is the decision for colorectal resection justified by histopathologic findings: a prospective study of 100 patients with advanced ovarian cancer. Gynecol Oncol. 2001; 83:481-4.
• [14]Sala E, Rockall A, Rangarajan D, Kubik-Huch RA. The role of dynamic contrast-enhanced and diffusion weighted magnetic resonance imaging in the female pelvis. Eur J Radiol. 2010; 76:367-85.
• [15]Nam EJ, Yun MJ, Oh YT, Kim JW, Kim JH, Kim S et al.. Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. Gynecol Oncol. 2010; 116:389-94.
• [16]Höckel M, Horn LC, Einenkel J. (Laterally) extended endopelvic resection: surgical treatment of locally advanced and recurrent cancer of the uterine cervix and vagina based on ontogenetic anatomy. Gynecol Oncol. 2012; 127:297-302.
• [17]Muraji M, Sudo T, Iwasaki S, Ueno S, Wakahashi S, Yamaguchi S et al.. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery. Gynecol Oncol. 2013; 131:531-4.
• [18]Hynninen J, Lavonius M, Oksa S, Grénman S, Carpén O, Auranen A. Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy? Gynecol Oncol. 2013; 128:229-32.